Ignite Creation Date:
2024-05-06 @ 6:29 PM
Last Modification Date:
2024-10-26 @ 2:48 PM
Study NCT ID:
NCT05676450
Status:
RECRUITING
Last Update Posted:
2024-05-09
First Post:
2022-12-15
Brief Title:
Feasibility and Clinical Utility of Cell-free DNA cfDNA in Identifying Actionable Alterations and Minimal Residual Disease for Lymphoma Patients Across Community Centers in Texas
Sponsor:
MD Anderson Cancer Center
Organization:
MD Anderson Cancer Center
Study Overview
Official Title:
Feasibility and Clinical Utility of Cell-free DNA cfDNA in Identifying Actionable Alterations and Minimal Residual Disease for Lymphoma Patients Across Community Centers in Texas
Status:
RECRUITING
Status Verified Date:
2024-05
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
To test the feasibility of collecting cell-free DNA cfDNA samples from DLBCL patients before and after treatment cfDNA is DNA traveling in your blood outside of a cell and is easily collected from blood samples drawn using the vein puncture method
Detailed Description:
Primary Objective
To determine the feasibility and clinical utility of ctDNA in identifying actionable alterations and minimal residual disease for lymphoma patients across community centers in Texas
Secondary Objectives
To provide useful prognostic information before treatment assess molecular response at interim time points and residual disease at the end of therapy and identify tumor-specific mutations
Levels of cfDNA and its association with both EFS and OS in patients receiving therapy
To determine the feasibility and clinical utility of ctDNA in identifying actionable alterations and minimal residual disease for lymphoma patients across community centers in Texas
Secondary Objectives
To provide useful prognostic information before treatment assess molecular response at interim time points and residual disease at the end of therapy and identify tumor-specific mutations
Levels of cfDNA and its association with both EFS and OS in patients receiving therapy
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| NCI-2022-10562 | OTHER | NCI-CTRP Clinical Trials Registry | None |